Zaid Admani

They've also partnered with Nvidia last summer to build a supercomputer specifically for drug research.

And Novo isn't the only pharma giant trying to get ahead with AI.

Eli Lilly announced a deal last month with Insilico Medicine, which is a Chinese-based AI drug discovery company.

So you're seeing all the big pharma players race to integrate AI into their pipeline right now.

And it makes sense because typically it takes years to develop a new drug.

If AI can cut that time down, it could be worth billions of dollars for these companies.

Nova Nordisk shares are up around 3% this morning in reaction to the OpenAI news.

Now, on the flip side, CarMax is getting crushed this morning after reporting earnings.

Now, the headline numbers did beat expectations.

Both revenue and earnings both came ahead of Wall Street estimates.

The problem though is that CarMax isn't growing.

Revenue fell 1% year over year in 2025 and same store vehicle sales dropped 2%.

This is now the fourth straight year of declining sales for the company.

Now CarMax did bring on a new CEO last month.

His name is Keith Barr and we'll have to see if he can turn things around.

Now CarMax didn't offer up a sales guidance for the full year, which is usually not a good sign.

And that's why CarMax stock is down more than 10% this morning at the time of this recording.

He's the Michael Jordan of copying other companies' core innovation.

Now, 10 years ago, he ripped off stories from Snapchat and added that in as a feature on Instagram.

And then in 2020, he copied TikTok and added that in as Reels, and it's been a huge success.